Cytosorbents AI Stock Analysis
Want to see CTSO full AI Analyst Report?
Cytosorbents (CTSO) AI Stock Analysis
Cytosorbents
(NASDAQ:CTSO)
CTSO’s score is held back primarily by weak financial fundamentals—deep losses, negative TTM operating/free cash flow, and a stressed balance sheet with negative equity and meaningful debt. Partially offsetting this are improving operational trends discussed on the earnings call (gross margin expansion and near/breakeven operating cash flow) and mildly improving near-term technical momentum, while valuation remains constrained by ongoing unprofitability.
Cytosorbents (CTSO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $16.17M
- Dividend Yield
- ―
- Average Volume (3M)
- 36.93K
- Price to Earnings (P/E)
- -1.0
- Beta (1Y)
- 0.99
- Revenue Growth
- 9.04%
- EPS Growth
- -44.94%
- Country
- US
- Employees
- 129
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Cytosorbents Business Overview & Revenue Model
Company Description
Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's lea...
How the Company Makes Money
CytoSorbents makes money primarily by selling its CytoSorb hemoadsorption cartridges and related consumables for use in hospitals, with revenue recognized when products are delivered/used according to customer contracts. The company’s key revenue str...
Cytosorbents Earnings Call Summary
The call was predominantly positive. The company achieved operating cash flow breakeven, substantially improved gross margin and adjusted EBITDA, reduced operating costs and cash usage, and reported progress in rebuilding commercial capacity and advancing DrugSorb-ATR and HemoDefend-BGA. The principal challenges were the approximately 20%-21% decline in Germany, a higher nine-month net loss caused by a non-cash foreign currency swing, the possibility of future quarters with modest cash burn, outstanding Nasdaq and debt-restructuring requirements, and uncertainty around regulatory approval and timing.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management is targeting product gross margins consistently in the mid-70% range and expects to remain at or near operating cash flow break-even, while noting that break-even will not be a straight line, every quarter will not be positive, and some quarters may show a modest burn and others a modest positive cash flow; it is actively working to satisfy the remaining Nasdaq listing requirement and debt restructuring by the end of this year, plans to add another German sales representative next month and two more by early 2027, expects a new BRILINTA De Novo submission in early 2027 subject to necessary work and regulatory interactions with a decision by FDA 150 days later, expects a separate Eliquis and Xarelto submission in 2027, and estimates an initial U.S. and Canadian addressable market of approximately $300 million to start, potentially expanding to $1 billion- $2 billion.
Cytosorbents Financial Statement Overview
Summary
Despite strong and stable ~70%+ gross margins and a sharp TTM revenue rebound (~65%), CTSO remains deeply unprofitable (TTM net margin ~-49%) with ongoing operating losses. Cash flow is still negative in TTM (operating cash flow ~-6.8M; FCF ~-6.9M), and the balance sheet is pressured by negative equity (~-2.3M) alongside rising debt (~29.6M), increasing financing/dilution risk.
Income Statement
28NegativeBalance Sheet
18Very NegativeCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 37.46M | 37.06M | 35.59M | 31.08M | 34.69M | 40.11M |
| Gross Profit | 27.31M | 26.49M | 24.89M | 21.95M | 20.73M | 29.06M |
| EBITDA | -12.03M | -4.36M | -19.27M | -27.88M | -29.75M | -24.17M |
| Net Income | -16.88M | -8.20M | -20.72M | -29.25M | -32.81M | -24.56M |
Balance Sheet | ||||||
| Total Assets | 37.16M | 44.18M | 47.37M | 53.26M | 63.23M | 89.52M |
| Cash, Cash Equivalents and Short-Term Investments | 4.21M | 6.25M | 3.28M | 14.13M | 22.14M | 52.14M |
| Total Debt | 29.57M | 29.11M | 26.89M | 18.31M | 18.25M | 13.82M |
| Total Liabilities | 39.47M | 38.28M | 36.26M | 29.99M | 27.86M | 26.94M |
| Stockholders Equity | -2.31M | 5.90M | 11.11M | 23.28M | 35.37M | 62.58M |
Cash Flow | ||||||
| Free Cash Flow | -8.12M | -12.54M | -14.71M | -22.59M | -34.69M | -18.29M |
| Operating Cash Flow | -8.00M | -12.38M | -14.43M | -21.66M | -28.23M | -14.01M |
| Investing Cash Flow | -380.00K | -415.00K | -669.43K | -936.24K | -6.46M | -4.28M |
| Financing Cash Flow | 2.48M | 9.31M | 9.33M | 14.47M | 4.96M | 715.20K |
Cytosorbents Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTSO, the sentiment is Positive. The current price of 5.13 is above the 20-day moving average (MA) of 4.93, above the 50-day MA of 4.75, and below the 200-day MA of 8.90, indicating a neutral trend. The MACD of 0.11 indicates Negative momentum. The RSI at 51.89 is Neutral, neither overbought nor oversold. The STOCH value of 46.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CTSO.
Cytosorbents Risk Analysis
Cytosorbents disclosed 39 risk factors in its most recent earnings report. Cytosorbents reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksCytosorbents Peers Comparison
Overall Rating
CTSO49Neutral
TELA44Neutral
BDMD42.1Neutral
ECOR42Neutral
ICCM42Neutral
MDAI41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | $16.17M | -0.96 | -1339.98% | ― | 9.04% | -44.94% | |
| 44Neutral | $32.84M | -0.98 | 425.91% | ― | 1.46% | 15.79% | |
| 42Neutral | $5.82M | -0.19 | -48.23% | ― | ― | ― | |
| 42Neutral | $44.75M | -3.39 | 498.83% | ― | 27.26% | 20.47% | |
| 42Neutral | $5.55M | -0.19 | -180.46% | ― | 31.80% | 27.37% | |
| 41Neutral | $42.16M | -3.98 | 100.93% | ― | -38.62% | 55.03% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CTSO | Cytosorbents Corp | 5.13 | -9.00 | -63.70% | |
| ECOR | Electrocore | 4.85 | 0.14 | 2.97% | |
| TELA | Tela Bio, Inc. | 0.73 | -0.44 | -37.95% | |
| MDAI | Spectral Ai, Inc. Class A | 1.31 | -0.12 | -8.39% | |
| ICCM | Icecure Medical Ltd. | 1.00 | -18.80 | -94.96% | |
| BDMD | Baird Medical Investment Holdings Ltd | 0.10 | -1.31 | -92.70% |
Cytosorbents Corporate Events
CytoSorbents Regains Nasdaq Compliance, Pursues Growth Initiatives
PositiveOn September 22, 2026, CytoSorbents regained compliance with Nasdaq’s minimum bid price rule after its shares closed at or above $1.00 for 10 consecutive trading sessions, leading Nasdaq to close the matter the following day. The company remains out...
CytoSorbents Announces One-for-Twenty Reverse Stock Split
NeutralOn September 3, 2026, CytoSorbents announced that it would implement a one-for-twenty reverse stock split of its common stock, following shareholder approval at its August 13, 2026 annual meeting. The company filed an amendment to its certificate of...
CytoSorbents Shareholders Approve Governance Measures and Reverse Split
PositiveCytoSorbents Corporation held its 2026 Annual Meeting of Stockholders on August 13, 2026, with a quorum of 42,487,327 shares represented out of 62,842,748 outstanding. Stockholders elected five directors to serve until the 2027 meeting and approved,...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
